NIH/SBA SBIR/STTR Vetted | Phase I and Phase II Funded | Academically Validated | FDA-Acceptable Non-GLP Preclincal Data | >40% Animal Reduction (FDA 3Rs Initiative Compliant)
THE WORLD'S FIRST AND ONLY DYNAMIC, WHOLE-BODY, REAL-TIME, MINIMALLY INVASIVE
IN VIVO DISCOVERY IMAGING TECHNOLOGY
NIH/SBA SBIR/STTR Vetted | Phase I and Phase II Funded | Academically Validated | Preclinical Data for IND Submissions | >40% Animal Reduction (FDA 3Rs Initiative Compliant)
See Candidate-Induced Tissue Damage Before Traditional Methods Detect Anything And
Catch What Traditional Methods Miss
When traditional safety methods miss, the cost is measured in failed Phase I trials, withdrawn drugs, and SUSAR events that could have been avoided.
From the originators and inventors of Discovery Imaging comes TITAN™ — the world's only FDA-acceptable, whole-body, real-time, dynamic in vivo imaging platform developed and exclusively offered by Durametrix.
Our clients come to Durametrix to:
✓ Detect cytotoxic tissue damage days before biomarkers signal
✓ Prioritize candidates with the strongest safety and efficacy profiles
✓ Strengthen due diligence in asset acquisitions and licensing
✓ Reduce SUSAR risk before candidates reach human trials
✓ NIH/SBA SBIR/STTR Phase I & II Funded
✓ Publications in Top Peer-Reviewed Journals including Clinical Cancer Research, Apoptosis, & Journal of Nuclear Medicine
✓Academically Validated Technology at Prestigious Academic Institutions
✓ Only Platform Of Its Type Worldwide (No Known Direct Competitors or Fakes)
✓ FDA 3Rs Compliant (Exceeds 40% Animal Reduction)
THE $2.6 BILLION PRECLINICAL PROBLEM
90% of Clinical Drug Development Fails
Stage of Development | Attrition Rate | Primary Cause of Failure |
|---|---|---|
Discovery to IND | 90% | PK/PD & Target Organ Toxicity |
Phase I (Safety) | 48% | Unforeseen Human Toxicity |
Phase II (Efficacy) | 71% | Lack of Clinical Effect |
"The True Cost of Traditional Tox: It’s not just the study cost; it’s the $40M 'False Start.' Our dynamic whole-body monitoring allows for earlier 'No-Go' decisions, preserving your capital for candidates that actually have a chance to reach the clinic."
WHY TRADITIONAL TOXICOLOGY FAILS:
⏱
TOO SLOW
6-8 Months Per Study
Pipeline Stalled
🎯
INCOMPLETE COVERAGE
Only Sampled Tissues
Missed Heterogeneous Tissue Damage
⚠️
TOO LATE
Biomarkers Failed To Elevate Until After Significant Damage Occurs
💰
TOO
EXPENSIVE
$500K-$2.5M Per Candidate
Synthesis Costs
Too Budget-Constrained To De-Risk Multiple Candidates
Static Snapshots vs. Dynamic Reality:
Standard histology is a "point-in-time" post-mortem analysis. It misses the progression of damage and early physiological triggers that only real-time, longitudinal monitoring can capture.
The "Target Organ" Blind Spot:
Traditional methods are biased—scientists typically only examine the organs they expect will be affected. If your candidate causes unforeseen toxicity in a non-target tissue, it remains a "hidden killer" until Phase I.
Sacrificial Data Gaps:
Relying on different animal cohorts for different time points creates "data noise." This lack of continuity makes it nearly impossible to map a clear, whole-body safety profile for a single candidate.
Lack of Translational Insight:
2D tissue slices don't replicate 3D human biology. Without whole-body dynamic context, you are essentially flying blind into your first human trial.
Severe Budgetary Constraints:
Traditional toxicology is a "binary" outcome (Pass/Fail) at the very end of a study. By the time a safety signal is detected via histology, millions have already been sunk into a doomed candidate. There is no "mid-study pivot" in traditional models.
INTRODUCING TITAN™: THE WORLD'S FIRST AND ONLY WHOLE-BODY, REAL-TIME MINIMALLY INVASIVE IN VIVO DISCOVERY IMAGING TECHNOLOGY PLATFORM
DO WHAT NO OTHER TECHNOLOGY CAN DO WITH TITAN™:
TRADITIONAL APPROACH | TITAN™ |
|---|---|
Terminal sacrifice required | Animals alive entire study |
Different animals/timepoints | SAME animals tracked over time |
2D tissue sections only | 3D whole-body coverage |
Single endpoint | Dynamic progression (4+ timepoints) |
6-8 months timeline | Starting at 10-12 weeks (depending on model) |
$500K-$2.5M per candidate | $150K-$250K per candidate |
100+ animals needed per candidate | 12-14 animals (>40% reduction) per candidate |
Biomarkers detect late or miss | Detects earlier and catches what has been missed with traditional studies |
Sampling bias (missed damage) | Comprehensive systemic, dynamic, organ and whole-body views |
Simultaneous approaches difficult and/or cumbersome | Can easily couple with other methods (e.g. CMP, Histology etc.) |
Defining a New Standard in Translational Safety
We didn't just attempt to build a better CRO service; we engineered a new category of Pre-clinical Certainty. Most CROs offer data. We offer Visualized Fate. As the only provider of dynamic, whole-body candidate-induced tissue damage detection, we don't compete with traditional toxicology—we supplement and replace its blind spots.
Academically Validated | NIH-Funded | SBA-Vetted | FDA-Aligned | Results Driven
COMPREHENSIVE SYSTEMIC INTELLIGENCE FROM ONE STUDY
Perfect Correlation from the Same Animals!
Because imaging is minimally invasive (simple IV injection + brief scan), animals remain alive throughout the study. This means we deliver EVERYTHING from the SAME animals—perfect correlation impossible with traditional methods.
WHOLE BODY IMAGING
- Baseline + 4 time points
(Days 1, 3, 5, 7)
- 3D visualization of tissue damage
- Quantitative analysis across all organs
- Real-time progression tracking
CLINICAL BIOMARKERS
- CMP (Comprehensive Metabolic Panel)
- CBC (Complete Blood Count)
- Measured at each imaging time point
- Trend analysis over time
HISTOPATHOLOGY OPTIONS
- H&E staining (all major organs)
- TUNEL (cell death confirmation) - IHC (2 custom markers)
- Board-certified pathologist review
THE DURAMETRIX ADVANTAGE:
Since animals remain alive throughout a study, we can correlate findings across all three modalities:
DYNAMIC IMAGING shows WHERE and WHEN damage occurs (4D whole-body mapping)
↓
BIOMARKERS confirm SEVERITY at each timepoint (CMP/CBC trends)
↓
HISTOPATHOLOGY validates WHAT happened at tissue level (H&E, TUNEL, IHC) All from the same animals. All at defined timepoints.
RESULT: You see damage progression in real-time, track biomarker changes in the same subjects, and confirm tissue-level pathology at study end, creating an ironclad dataset traditional methods cannot provide. No more wondering: "Was the imaging artifact real? Which animals showed the biomarker changes? Did we sample the right tissue region?" With TITAN™ everything correlates. Everything connects, allowing you to De-risk and De-prioritize faster and more efficiently!
═══════════════════════════════════════════════════════════
REAL-WORLD EXAMPLES FROM PUBLISHED STUDIES
═══════════════════════════════════════════════════════════
EXAMPLE 1: Bridging the Diagnostic Gap
NEPHROTOXICITY DETECTION
Published: Clinical Cancer Research, 2019
Model: Sprague Dawley Rats
Drug: Cisplatin
Dose: 2.5 mg/kg, Single Dose I.P. Administration
Visualization: Day 5 Post-Treatment
Parameter | Result (Mean ± SD) | Typical Rat Range | Interpretation |
|---|---|---|---|
Albumin | 2.89 ± 0.12 g/dL | 2.5 – 4.0 g/dL | Normal. This is comfortably within the expected range for a healthy adult rat. |
BUN | 15.27 ± 4.48 mg/dL | 10 – 25 mg/dL | Normal. This indicates the kidneys are processing nitrogenous waste effectively. |
Creatinine | 0.29 ± 0.12 mg/dL | 0.2 – 0.8 mg/dL | Normal (Low-End). This is a healthy reading, though very low values sometimes reflect low muscle mass. |
BUN/Creatinine | 54.93 ± 11.74 | 20 – 35 (approx.) | High. This ratio is significantly elevated. |
The Diagnostic Trap: A ratio of ~55 with "normal" Creatinine is frequently dismissed in research as mild dehydration or dietary fluctuation. Without imaging, the underlying pathology may be missed.
Direct Tissue Visualization: While the blood chemistry suggested the rats were "healthy but dehydrated," Discovery Imaging with TITAN™ provides clear, direct evidence of cortical tissue damage bilateral kidney signal with noted elevated radioactivity uptake in cortical regions showing spatiotemporal elements of tissue damage. This technology identified the specific anatomical regions under stress long before the functional output of the kidneys (Creatinine) was compromised. Histopathology confirms acute tubular damage confirmed in cortical region with enhanced apoptosis via TUNEL and H&E staining validates imaging findings structural damage visible at tissue level.
Insight: The elevated BUN/Creatinine ratio was not dehydration; it was the metabolic "smoke" from early-stage intrinsic renal injury.
The Conclusion: Sensitivity Matters
TITAN™ revealed that considerable tissue damage was already evident, pinpointing the "Silent Window"—the crucial time frame when tissue damage occurs without yet compromising function. By offering direct visualization of tissue changes, TITAN™ highlights the "Silent Window," allowing for:
-
Earlier Detection: Spot injuries days ahead of standard biomarkers indicating "failure."
-
Increased Sensitivity: Differentiate between metabolic noise (such as a high BUN/Creatinine ratio) and genuine structural necrosis.
-
Higher Confidence: Correlate imaging hotspots with histopathological validation
-
Early damage identification compared to traditional serum biomarkers.
-
Elimination of ambiguity in statistically significant but "clinically normal" blood results.
-
Reduction of animal count by obtaining definitive structural data from each subject.
"Direct visualization of tissue damage provides a sensitivity advantage that standard clinical chemistry panels simply cannot match."
— Reference: Johnson et al., Clinical Cancer Research, 2019
EXAMPLE 2: COMPREHENSIVE MULTI-ORGAN ASSESSMENT
Quantitative 4D Analysis
Same Animal Set from Example 1 Expanded
Published: Clinical Cancer Research, 2019
Model: Sprague Dawley Rats
Drug: Cisplatin
Dose: 2.5mg/kg, Single Dose I.P. Administration
Visualization: Day 5 Post-Treatment
Quantitative 4D Mapping
4D plot map transforms a single time point into a comprehensive systemic analysis, providing deep insights into both the individual subject and the broader cohort.
✓ Individual Animal Tracking
-
Identify subject variability and specific progression markers within the cohort
✓ Population-Level Trends Across Cohort
-
Visualize overall cohort patterns visible while maintaining high-resolution individual data
-
Maximize statistical power from complete datasets
✓ Multi-Organ Toxicity Patterns
-
Capture damage across the WHOLE BODY simultaneously - Not just single primary target organs/tissues
-
Comprehensive organ coverage in single visualization
-
In-depth systemic analyses possible in same animals in real time
✓ Tissue-Specific Response Profiles
-
Reveal how different tissues/organs exhibit different kinetics and severity
-
Heterogeneous cytotoxic tissue damage patterns revealed
Exploratory Toxicology: The Power of Total Visibility
Moving from "Selective Sampling" to Whole-Body Certainty
In conventional toxicology, researchers are forced to gamble on which tissues to examine. If damage occurs in an unexpected or unforeseen site, it is lost. TITAN™ minimizes this risk by capturing the WHOLE BODY in a single, quantitative 4D visualization providing simultaneous systems-, individualized- and population-based data.
RESULT: Beyond Predicted Pathology
Standard protocols require you to SELECT which organs to examine (typically 5–10 tissues like the Liver, Kidney, and Heart). With TITAN™, you SEE EVERYTHING.
-
Comprehensive Coverage: All organs and tissues are captured in a single whole-body scan, including a standard list of 22 tissues analyzed in every scan that can be expanded, reduced, or otherwise customized to each sponsor's needs.
-
Discovery-Driven: No prediction needed. You don't have to be looking for a specific site of injury to catch it.
-
Systemic Clarity: Identify heterogeneous cytotoxic tissue damage patterns that localized biopsies may miss.
The Comparison: Why Whole-Body Matters
Traditional Approach | TITAN™ Advantage |
|---|---|
Selective: Must predict 5–10 expected tissues. | Global: Every tissue captured in one scan. |
High Risk: Damage in unsampled tissue is MISSED. | Total Security: Catch what's missed; no prediction required. |
Localized: Deep dive into limited areas. | Systemic: In-depth analysis of the entire system in real-time. |
"TITAN™ provides exploratory toxicology at its most powerful—seeing everything, missing nothing, and providing the certainty that if damage exists anywhere in the body, it is accounted for."
EXAMPLE 3: DYNAMIC PROGRESSION TRACKING
Published: Clinical Cancer Research, 2019
Model: Sprague Dawley Rats
Drug: Cyclophosphamide
Dose: 80 mg/kg, Single Dose I.P. Administration
Visualization: Dynamic Through Day 7 Post-Treatment
Cyclophosphamide Cytotoxicity — Longitudinal Imaging
Traditional toxicology relies on "snapshots" of different animals sacrificed at separate intervals, creating a fragmented view of drug effects. TITAN™ captures the entire story by tracking the same animals across the entire study duration.
Importantly Each Subject Is Its Own Baseline Control Simultaneously Allowing for Dynamic Individualized and Population-Based Analyses! NO MORE MISSING!
Dynamic imaging of cyclophosphamide treated rats. Signal changes in representative tissues from male rats before and 1, 3, 5 and 7 days after cyclophosphamide treatment (80 mg/kg, single dose). SPECT/CT fusion images demonstrate signal changes in the gut (A), thymus (B), kidneys (C), spleen (D) and femurs/knees (E) over the course of 7 days after treatment. Note that the onset and progression of tissue injury differ in a spatiotemporal fashion.
WHAT THIS DEMONSTRATES:
✓ Individual Animal Tracking Over Time
-
Each animal's response tracked across multiple timepoints
-
See individual subject variability and progression
✓ Population-Level Trends Across Cohort
-
Overall patterns visible while maintaining individual resolution
-
Statistical power from complete dataset
✓ Multi-Organ Toxicity Patterns
-
Not just target organ—ALL tissues captured simultaneously
-
Comprehensive organ coverage in single visualization
-
In-depth systemic analyses possible in same animals in real time
✓ Temporal Progression Dynamics
-
Baseline through Day 7 changes clearly visible
-
Dynamic damage progression tracked continuously
✓ Tissue-Specific Response Profiles
-
Different organs show different kinetics and severity
-
Heterogeneous cytotoxic tissue damage patterns revealed
-
True spatiotemporal dynamics of tissue damage
TRANSFORMATIVE DATA:
Dynamic Whole-Body Quantitative Assessments
Moving Beyond the Limitations of Terminal Sacrifice
Traditional toxicology relies on "snapshots" that often miss the full story of drug distribution and organ toxicity. TITAN™ replaces predictive sampling with comprehensive, longitudinal visualization.
The Longitudinal Advantage
Unlike conventional methods that require a "sacrifice and sample" approach, TITAN™ allows for the continuous monitoring of the same subject, reducing noise and increasing statistical power.
In conventional studies:
x Different animals sacrificed at each timepoint
x Only selected tissues sampled (you must predict which to examine)
x Individual animal progression cannot be tracked
x Incomplete organ coverage (miss unexpected toxicity sites)
TITAN™ provides:
✓Same animals tracked throughout (true longitudinal data)
✓Every organ captured simultaneously (comprehensive coverage)
✓Individual AND population-level insights from single dataset
✓Quantitative progression curves for all tissues
This is exploratory toxicology at its most powerful—seeing everything, missing nothing, tracking progression in real-time.
Quantitative Progression Curves
TITAN™ doesn't just provide pictures; it provides data. By capturing the entire subject, we generate precise kinetic curves for every organ from a single dataset. This allows researchers to identify:
-
Off-target accumulation in tissues that were not originally under suspicion.
-
Individual vs. Population-level insights, allowing for the identification of "responders" and "non-responders" within the same study.
The Conclusion: Power Through Insight
This is exploratory toxicology at its most powerful. By tracking the exact same animal from Day 0 to the study's end, you eliminate the "biological noise" of multi-animal cohorts and uncover the true kinetic profile of your candidate.
"TITAN™ allows for the discovery of unexpected targets and sites that traditional, localized sampling would ignore. It is the difference between guessing where to look and seeing the whole truth."
The 3Rs Advantage: Maximizing Data, Minimizing Subjects
TITAN™ redefines study efficiency by extracting significantly more data from fewer subjects. By shifting from terminal "snapshots" to longitudinal "films," researchers can achieve higher statistical power with a fraction of the traditional animal count.
Redefining Efficiency
The ability to track individual progression across the entire body simultaneously transforms the economics and ethics of toxicology:
-
Reduction: Eliminate the need for "satellite groups" or separate cohorts for every time point. One group provides the entire temporal curve.
-
Refinement: Non-invasive, real-time tracking allows for earlier detection of "humane endpoints," reducing animal distress through better monitoring.
-
Replacement of Uncertainty: Traditional methods rely on "predictive sampling." If you don't sample the spleen, you don't find the toxicity. TITAN™ captures every organ, replacing guesswork with total visibility.
EXAMPLE 4: SIMULTANEOUS TUMOR EFFICACY + COLLATERAL CYTOTOXICITY DISCOVERY
Published: Apoptosis, 2025
Model: OPM-2 Tumor SCID-Beige Mice
Drug: Bortezomib
Dose: 1 mg/kg, Single Dose I.V. Administration Every 4 Days
Visualization: Dynamic
One Study, Dual Assessment:
Therapeutic Benefit + Safety Profile
In traditional drug development, efficacy studies and safety/toxicology studies are conducted as separate, siloed experiments. TITAN-RX™ breaks this barrier, allowing researchers to measure how well a drug kills a tumor while simultaneously identifying exactly where it causes collateral damage—all within the same subject.
Therapeutic Benefit: Anti-Tumor Efficacy
SECTION 1: THERAPEUTIC PERFORMANCE (Efficacy + Validation)
By combining real-time imaging with "gold-standard" histology, we confirm the drug's mechanism of action (apoptosis) is occurring exactly where predicted.
-
Imaging Data: Progressive tumor cell death signal with quantitative uptake increase.
-
Histology Validation: TUNEL staining confirms massive apoptosis within the tumor.
-
Conclusion: Efficacy is unambiguous—the drug is successfully killing tumor cells.
Safety Profile Simultaneous Collateral Cytotoxicity
SECTION 2: OFF-TARGET COLLATERAL CYTOTOXICITY
While the drug successfully targeted the tumor, TITAN™ automated whole-body screening also identified statistically significant toxicity in tissues not typically examined in efficacy protocols.
-
Dynamic Imaging Data: Systemic Significance (Dynamic Bar Graph)
-
A global overview of radioactivity uptake across all tissues. Stars indicate organs where signal intensity reached statistical significance (p<0.05), providing an immediate "heatmap" of off-target risk.
-
-
Kinetic Expansion (Organ-Specific Profiles)
-
Detailed progression curves for identified tissue. This identifies which tissues face early-stage vs. chronic accumulation.
-
-
Visual Evidence (Peak Toxicity Snapshots)
-
High-contrast visual confirmation for each designated organ at the peak of the toxicity phase, correlating the quantitative data with anatomical pathology.
-
Representative images of elevated radioactivity uptake in treated tissues. A Adipose tissue (arrows); B Abdominal region (block arrows); C Epiphysis of the femur (arrows); D Spleen (arrow); and E Testis (arrow). Left—control, right—treated. The radioactivity uptake was normalized to the total injected radioactivity dose
RESULT: The Integrated Truth
TITAN™ captures both therapeutic effect AND collateral tissue damage in a single integrated study providing the "Total Truth" of an oncologic candidate. You no longer have to choose between an efficacy study and a safety screen—you receive both.
-
✓ Efficacy Assessment: Tumor kill confirmed by imaging and validated by histology.
-
✓ Safety Screening: Off-target cytotoxicity identified in organ systems without prior prediction. These findings correlate with known toxicity profiles for this drug class, but were captured here in a single, standard efficacy study.
Reference: Johnson et al., Apoptosis, 2025
═════════════════════════════════════════════════════════════Published Methodology. Proven Reliability.
The quantitative analysis and imaging protocols powering the TITAN™ platform are built upon a foundation of 13+ peer-reviewed studies. Our methodology is trusted by independent researchers and published in high-impact journals.
-
Clinical Cancer Research (IF: 11.5) – Quantitative imaging for toxicology.
-
Apoptosis – Mechanism-based off-target discovery.
-
13+ Publications – Supporting our systemic analysis and 4D mapping.
═════════════════════════════════════════════════════════════
Predictable Investment. Unparalleled Data.
A New Standard in Transparent, Productized CRO Services
We’ve standardized our rodent imaging (mouse and rat) and pathology protocols to eliminate the "quote-lag" of traditional models so that all you have to do is choose the tier that matches your research stage and move from inquiry to delivering data that matters with unprecedented speed.
Imaging Only
$150K / candidate
Systemic Bio-distribution
Whole-body SPECT/CT mapping for rapid lead ranking...
View Tier Details →
Standard Integration
$200K / candidate
Integrated Validation
Core imaging integrated with clinical chemistry and pathology...
View Tier Details →
⭐Most Popular⭐
Comprehensive Discovery
$250K / candidate
The "Total Truth" Suite
High-resolution MRI and molecular validation for deep-dive discovery...
View Tier Details →
*Pricing is based on standard rodent models (Mouse/Rat) and established tracer protocols. Custom studies quoted separately. Final investment is contingent on project complexity, specific tracer requirements, and study depth.*
Strategic Portfolio Scaling
Standardizing lead optimization across your library.
Maximize your R&D budget by moving from individual studies to a pipeline-integrated model. These packages consolidate our full service suite into a high-throughput workflow.
-
Project Package (10+ Compounds): $180K / compound
-
Pipeline Package (20+ Compounds): $150K / compound
-
Includes the full Standard Integration suite (Imaging + Chemistry + Pathology).
*Pipeline and Project packages assume a standardized protocol across the compound library to maximize operational efficiency.*
*TITAN™ deliverables are for exploratory research and discovery purposes only. All off-target and collateral tissue findings are intended to guide internal R&D decisions and do not constitute a formal regulatory toxicology conclusion.*
WHO WE SERVE
Exploratory Research for Every Stage of Drug Development
01. BIOTECH STARTUPS
Seed → Series C | <200 Employees
The Challenge: You’re racing to milestones with limited runway. Traditional exploratory screening often burns 6 months and significant capital before you even reach GLP. You can't afford to wait—or bet on the wrong candidate.
The TITAN™ Advantage:
-Rapid Throughput: Results in 12–16 weeks vs. 6+ months traditional models.
-Capital Efficiency: $200K per candidate vs. $500K+ for fragmented vendor management.
- Strategic De-Risking: Test 3–5 candidates for the price of one traditional pilot study.
Typical Engagement:
- Standard Integration: $200K per compound
-Multi-Compound (3-5): $180K each
02. MID-SIZE PHARMA & BIOTECH
$200M – $1B Revenue | 200–1,000 Employees
The Challenge: Preclinical models often fail to predict Phase I safety signals. With Phase I failures costing $10M+, you need a "Total Truth" assessment before committing to the massive expense of GLP validation.
How We Help:
-Head-to-Head Screening: Compare 5–10 leads using identical systemic metrics.
-Off-Target Discovery: Identify specific mechanisms of insult for Pre-IND discussions.
- Integrated Validation: Confirm structural safety and efficacy in a single, unified study.
Typical Engagement:
- Standard Integration: $200K per compound
-Comprehensive (Total Truth): $250K per compound
03. LARGE PHARMA & BIOTECH
$1B+ Revenue | Strategic Partnerships | M&A, Business Development & Innovation Teams
The Challenge: For Enterprise teams, the ability to fail fast and de-prioritize early is a necessity. The risk isn't just the study cost—it’s the $500M+ liability of a bad acquisition or a missed safety signal in a licensed asset. Furthermore, managing fragmented vendors for high-volume pipeline screening is an operational nightmare that creates data silos and slows discovery. Research & Development, Safety, M&A, and BD teams all need rapid, objective "Total Truth" audits to verify asset integrity before committing to high-value acquisitions or licensing.
The Solutions:
-Includes All Mid-Size Discovery Benefits:
Systemic safety profiling, head-to-head lead ranking, and anatomical validation of off-target insult.
-Cost Containment: 30-compound programs delivered in <1 year at significant cost savings.
-M&A Due Diligence: Rapid whole-body auditing of acquired assets to identify hidden tissue damage and safety risks before closing the deal.
-Portfolio Prioritization: Standardized screening to de-prioritize assets with unfavorable safety profiles and focus resources on the highest-value candidates.
-Proof-of-Concept (POC) Partnerships: High-throughput factory for systemic data, freeing up internal resources for proprietary late-stage work
.
-Data Harmonization: Standardized SPECT/CT/Pathology protocols across all therapeutic areas.
Typical Engagement:
-Pipeline Pkg (20+): $150K per compound (Full Integrated Suite)
-Comprehensive (Total Truth): $250K per compound
-Strategic Audit/Due Diligence: Custom high-velocity protocols for M&A timelines.
REDUCE THE UNCERTAINTY IN YOUR PIPELINE.
═══════════════════════════════════════════════════════════
REDUCE UNCERTAINTY IN YOUR PIPELINE
════════════════════════════════════════════════ ═══════════
There is only one methodology that delivers whole-body, real-time in vivo imaging integrated with molecular biomarkers and systemic histopathology from the same subjects.
Stop flying blind. Start seeing the total truth.
SCHEDULE A PRE-STUDY TECHNICAL ASSESSMENT
Free 30-Minute Consultation
No sales pressure. Just a technical consultation from scientists who understand that data integrity is the only path to a successful IND. Evaluate your current safety data and identify where systemic imaging can provide the evidence you need to move forward or pivot with confidence.
-
Audit Your Pipeline: Review your compound's development stage and known target tissues.
-
Identify Blind Spots: Discuss current safety protocols and where "hidden" tissue insult might occur.
-
Technical Fit: Determine if TITAN™ anatomical validation is the right tool for your specific molecule.
-
Project Logistics: Provide custom timelines and a transparent investment estimate.
-
Technical Q&A: Address methodology, data integration, and regulatory context.
NOT READY TO BOOK? CONTINUE EXPLORING:
PREFER TO TALK NOW?
Phone: (414) 465-8654
Email: inquiries@durametrix.com
Our team reviews all inquiries daily. You can expect a response from a technical lead by the next business day.